ASMB

Assembly Biosciences, Inc.

36.56 USD

Last updated Sep 4, 20:41 UTC

Yesterday HIGH

$36.8

Yesterday LOW

$35.54

52w HIGH

$39.7

52w LOW

$20.23

EPS

-0.20

PE

-182.80

Next Earnings

Nov 9, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Assembly Biosciences, Inc. stock is up 37.75% since 30 days ago. The next earnings date is Nov 9, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 15 September’s closed higher than August. In the last 1 Unusual Options Trades, there were 1 CALL. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

17 Jul 16:00	21 Aug, 2026	30.00	CALL	150	8

Advanced Data Unlock

Avi Kapoor

Fri May 22, 2026

Crude Oil Edges Higher; US Consumer Sentiment Falls In May

US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low. Oil up, gold and silver down. European and Asian markets closed higher.
Avi Kapoor

Fri May 22, 2026

Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday

Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.
Benzinga Newsdesk

Fri May 22, 2026

Assembly Biosciences shares are trading higher after the company announced plans to expand the clinical development of ABI-6250. The company prices its $100 million offering of 3,358,602 shares at $26.50 per share.
Benzinga Newsdesk

Fri May 22, 2026

Assembly Biosciences Prices $100M Offering Of 3,358,602 At $26.50 Per Share And Warrants To Purchase Up To 415,000 Shares At Offer Price Of $26.499 Per Pre-Funded Warrant

Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten, registered offering (the
Benzinga Newsdesk

Fri May 22, 2026

Assembly Biosciences Announces Plans To Expand Clinical Development Of ABI-6250 Into Primary Biliary Cholangitis And Primary Sclerosing Cholangitis

"We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant unmet medical need despite existing PBC therapies, and in the case of PSC, no approved treatments," said Anuj Gaggar, MD,
Benzinga Newsdesk

Wed May 13, 2026

Assembly Biosciences To Present First-In-Class Oral Hepatitis D Virus Entry Inhibitor ABI-6250 Data At EASL Congress 2026
Benzinga Newsdesk

Thu May 7, 2026

Assembly Biosciences Q1 EPS $(0.54) Beats $(0.71) Estimate, Sales $8.213M Miss $9.266M Estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.71) by 23.94 percent. This is a 53.85 percent increase over losses of $(1.17) per share
Benzinga Newsdesk

Mon May 4, 2026

HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
Benzinga Newsdesk

Thu Apr 9, 2026

Assembly Biosciences Presents Phase 1b Data For ABI-5366 And ABI-1179 At ESCMID Global

– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –
Benzinga Newsdesk

Mon Apr 6, 2026

Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.

Mizuho

Tue Sep 1, 16:49

buy

confirm
UBS

Tue Sep 1, 14:53

buy

initial
HC Wainwright & Co.

Tue Aug 18, 12:32

buy

confirm